Prevalence of hepatitis B virus infection and uptake of hepatitis B vaccine among healthcare workers, Makueni County, Kenya 2017.


Journal

Journal of public health (Oxford, England)
ISSN: 1741-3850
Titre abrégé: J Public Health (Oxf)
Pays: England
ID NLM: 101188638

Informations de publication

Date de publication:
20 12 2019
Historique:
received: 01 08 2018
revised: 10 09 2018
pubmed: 24 10 2018
medline: 25 6 2020
entrez: 24 10 2018
Statut: ppublish

Résumé

Hepatitis B virus (HBV) is a vaccine-preventable infection that can spread in healthcare setting. Data on HBV infections and vaccine in African healthcare workers (HCWs) are limited. We estimated HBV infection prevalence, hepatitis B vaccination status and identified factors associated with vaccination in one Kenyan county. Randomly selected HCWs completed a questionnaire about HBV exposure and self-reported immunization histories, and provided blood for testing of selected HBV biomarkers to assess HBV infection and vaccination status: HBV core antibodies (anti-HBc), HBV surface antigen (HBsAg) and HBV surface antibodies (anti-HBs). Prevalence odds ratios (OR) with 95% confidence intervals (95% CI) were calculated to identify factors associated with vaccination. Among 312 HCWs surveyed, median age was 31 years (range: 19-67 years). Of 295 blood samples tested, 13 (4%) were anti-HBc and HBsAg-positive evidencing chronic HBV infection; 139 (47%) had protective anti-HBs levels. Although 249 (80%) HCWs received ≥1 HBV vaccine dose, only 119 (48%) received all three recommended doses. Complete vaccination was more likely among those working in hospitals compared to those working in primary healthcare facilities (OR = 2.5; 95% CI: 1.4-4.3). We recommend strengthening county HCW vaccination, and collecting similar data nationally to guide HBV prevention and control.

Sections du résumé

BACKGROUND
Hepatitis B virus (HBV) is a vaccine-preventable infection that can spread in healthcare setting. Data on HBV infections and vaccine in African healthcare workers (HCWs) are limited. We estimated HBV infection prevalence, hepatitis B vaccination status and identified factors associated with vaccination in one Kenyan county.
METHODS
Randomly selected HCWs completed a questionnaire about HBV exposure and self-reported immunization histories, and provided blood for testing of selected HBV biomarkers to assess HBV infection and vaccination status: HBV core antibodies (anti-HBc), HBV surface antigen (HBsAg) and HBV surface antibodies (anti-HBs). Prevalence odds ratios (OR) with 95% confidence intervals (95% CI) were calculated to identify factors associated with vaccination.
RESULTS
Among 312 HCWs surveyed, median age was 31 years (range: 19-67 years). Of 295 blood samples tested, 13 (4%) were anti-HBc and HBsAg-positive evidencing chronic HBV infection; 139 (47%) had protective anti-HBs levels. Although 249 (80%) HCWs received ≥1 HBV vaccine dose, only 119 (48%) received all three recommended doses. Complete vaccination was more likely among those working in hospitals compared to those working in primary healthcare facilities (OR = 2.5; 95% CI: 1.4-4.3).
CONCLUSION
We recommend strengthening county HCW vaccination, and collecting similar data nationally to guide HBV prevention and control.

Identifiants

pubmed: 30351408
pii: 5142651
doi: 10.1093/pubmed/fdy186
doi:

Substances chimiques

Hepatitis B Antibodies 0
Hepatitis B Surface Antigens 0
Hepatitis B Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

765-771

Subventions

Organisme : PEPFAR
Pays : United States

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of Faculty of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

E N Kisangau (EN)

Kenya Field Epidemiology and Laboratory Training Program (FELTP), Ministry of Health, Nairobi, Kenya.
School of Public Health, Moi University, Eldoret, Kenya.

A Awour (A)

Division of Global Health Protection, Centers for Disease Control and Prevention, Village Market, Nairobi, Kenya.

B Juma (B)

Division of Global Health Protection, Centers for Disease Control and Prevention, Village Market, Nairobi, Kenya.

D Odhiambo (D)

Kenya Medical Research Institute, Centers for Disease Control and Prevention Laboratory, Nairobi, Kenya.

T Muasya (T)

Kenya Medical Research Institute, Center for Virus Research, Hepatitis Laboratory, Nairobi, Kenya.

S N Kiio (SN)

County Department of Health, Makueni County, Kenya.

R Too (R)

School of Public Health, Moi University, Eldoret, Kenya.

S A Lowther (SA)

Division of Global Health Protection, Centers for Disease Control and Prevention, Village Market, Nairobi, Kenya.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH